Bayer AG (BAYZF)
62.54
+0.06
(+0.09%)
USD |
OTCM |
Nov 16, 16:00
Bayer Enterprise Value : 103.80B for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 103.80B |
| November 13, 2026 | 103.74B |
| November 12, 2026 | 103.47B |
| November 11, 2026 | 104.71B |
| November 10, 2026 | 104.60B |
| November 09, 2026 | 104.82B |
| November 06, 2026 | 101.82B |
| November 05, 2026 | 103.62B |
| November 04, 2026 | 101.72B |
| November 03, 2026 | 99.93B |
| November 02, 2026 | 97.14B |
| October 30, 2026 | 97.14B |
| October 29, 2026 | 93.76B |
| October 28, 2026 | 92.80B |
| October 27, 2026 | 92.03B |
| October 26, 2026 | 92.40B |
| October 23, 2026 | 90.87B |
| October 22, 2026 | 90.87B |
| October 21, 2026 | 90.87B |
| October 20, 2026 | 90.87B |
| October 19, 2026 | 90.30B |
| October 16, 2026 | 91.19B |
| October 15, 2026 | 91.46B |
| October 14, 2026 | 90.53B |
| October 13, 2026 | 90.53B |
| Date | Value |
|---|---|
| October 12, 2026 | 90.35B |
| October 09, 2026 | 90.56B |
| October 08, 2026 | 89.52B |
| October 07, 2026 | 92.00B |
| October 06, 2026 | 92.00B |
| October 05, 2026 | 90.98B |
| October 02, 2026 | 94.22B |
| October 01, 2026 | 91.51B |
| September 30, 2026 | 96.57B |
| September 29, 2026 | 93.55B |
| September 28, 2026 | 95.76B |
| September 25, 2026 | 94.85B |
| September 24, 2026 | 94.46B |
| September 23, 2026 | 94.95B |
| September 22, 2026 | 94.79B |
| September 21, 2026 | 94.32B |
| September 18, 2026 | 93.21B |
| September 17, 2026 | 94.57B |
| September 16, 2026 | 94.57B |
| September 15, 2026 | 95.60B |
| September 14, 2026 | 95.60B |
| September 11, 2026 | 94.68B |
| September 10, 2026 | 94.68B |
| September 09, 2026 | 94.68B |
| September 08, 2026 | 94.68B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck KGaA | 31.13B |
| Breakthrough Chemistry, Inc. | 0.0854M |
| Cardiac Biotech Solutions, Inc. | 6.406M |
| Fresenius SE & Co. KGaA | 45.10B |
| Carl Zeiss Meditec AG | 3.419B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -760.49M |
| Revenue (Quarterly) | 11.57B |
| Total Expenses (Quarterly) | 12.34B |
| EPS Diluted (Quarterly) | -0.787 |
| Gross Profit Margin (Quarterly) | 54.23% |
| Profit Margin (Quarterly) | -6.58% |
| Earnings Yield | -2.70% |
| Operating Earnings Yield | 10.91% |
| Normalized Earnings Yield | 2.885 |